Breast biopsy delayed by FDA needle shortage? What patients should ask now

The FDA says a U.S. shortage of stereotactic breast biopsy needles may disrupt care through the end of the first quarter of 2027. For some patients, that could mean a rescheduled appointment, a referral to another site, or a change in how the biopsy is done.

If you were told you need a breast biopsy, the most useful next step is to ask your imaging center or breast specialist how urgent your specific finding is and what the backup plan will be if your appointment changes.

What the FDA letter means in plain language

On June 16, 2026, the FDA told health care providers that the United States is experiencing supply interruptions for stereotactic breast biopsy needles. The agency said the shortage is expected to affect patient care and may last through the end of Q1 2027, or March 2027.

The FDA also noted that on January 2, 2026, Hologic issued a customer letter removing all lots of a disposable 9-gauge needle used with its Brevera Breast Biopsy System because metal or plastic particles could be dislodged during use. For patients, the practical takeaway is not that every biopsy will be canceled. It is that some facilities may need to conserve certain devices and adjust scheduling or referrals.

The FDA advised clinicians to communicate delays clearly, look for alternative biopsy locations when available, and keep the focus on minimizing delay in cancer diagnosis and treatment.

Where stereotactic breast biopsy fits after abnormal imaging

If a screening mammogram is abnormal, the CDC says doctors usually do more testing to find out whether the finding is cancer. That may include a diagnostic mammogram, ultrasound, MRI, or referral to a breast specialist. An abnormal screening result does not automatically mean cancer, and it does not automatically mean surgery.

A breast biopsy is the step that removes tissue or fluid so it can be examined under a microscope. MedlinePlus notes that most breast lumps and other changes checked with biopsy turn out to be benign, meaning not cancer.

Stereotactic breast biopsy is a mammography-guided biopsy. It is often used when the suspicious area is best seen on mammography, such as some calcifications or other findings that may not show up well on ultrasound. Depending on the lesion and what a facility can safely offer, some patients may instead be candidates for ultrasound-guided biopsy, MRI-guided biopsy, or another diagnostic approach.

What a delay could look like

A shortage-related delay will not look the same for every patient. The American College of Radiology says practices may respond in several ways, including using more targeted ultrasound before MRI-guided or stereotactic biopsy when appropriate, shifting some patients to ultrasound-guided biopsy when feasible, referring patients to another site with supplies, or delaying some lower-suspicion findings when short-interval follow-up is clinically appropriate.

At the same time, ACR says higher-priority cases may need to go first. That can include very suspicious lesions, cases connected to surgical planning, or situations where a delay could more directly affect treatment decisions.

So if one patient is rescheduled and another is not, that does not necessarily mean the center is handling cases inconsistently. It may reflect differences in the imaging finding, the type of biopsy needed, the local supply situation, or whether an alternative approach is available.

Questions to ask your imaging center or breast specialist now

How urgent is tissue diagnosis in my specific case?
Is my appointment being changed because of the current needle shortage, or for another reason?
What is my new target date for biopsy or repeat imaging?
Could ultrasound-guided biopsy or another clinically appropriate approach work for this finding?
If not, can I be referred to another site that has the needed supplies?
If the plan is short-interval follow-up instead of immediate biopsy, what exact test and timeline are being recommended?
Will a change in biopsy site or method require a new order, prior authorization, or other insurance paperwork?
Who should I call if I do not hear back by a specific date?

Those questions matter because scheduling, insurance rules, referral pathways, and available equipment can vary by health system and region.

What to watch for while you wait

If you are waiting for a biopsy or rescheduled imaging, do not let the plan stay vague. Ask for a specific next step, a target date, and the name of the office responsible for follow-up.

Also tell your care team promptly if you notice a new or changing breast lump, nipple discharge, or skin or nipple changes such as redness, scaling, swelling, or pulling inward. Those changes do not prove cancer, but they should not be ignored while you are waiting for follow-up.

What to expect next

If your biopsy goes ahead, MedlinePlus says results may take several days to a week. Ask how results will be delivered, who will explain them, and what the next step will be if the sample is benign, high-risk, or cancerous.

One retrospective study of 745 newly diagnosed breast cancer patients at a single academic center found a median of 12 days from abnormal mammogram to core biopsy, while 11% had a delay longer than 30 days. That study was done before the current shortage and cannot predict what will happen at your facility now. Still, it shows that follow-up timing can vary and that delays should be handled with clear communication and a documented plan.

Bottom line

The shortage is real, and the FDA expects it could affect care into March 2027. What is not yet known is how much any one patient’s timeline will change, whether an alternative biopsy method will work in a given case, or how uneven the shortage will be from one center to another.

The most practical next step is to ask how urgent your finding is, what alternatives are available, when your next appointment should happen, and who is responsible for making that plan happen. A delay should not be left as an open-ended wait.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.